| CAS NO: | 37413-91-5 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 37413-91-5 |
| 别名 | 21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 |
| Canonical SMILES | C[C@@]12[C@](CC=C2C(COC(C)=O)=O)([H])[C@@]3([H])C([C@@]4(C(CC3)=CC(C=C4)=O)C)=CC1 |
| 分子式 | C23H26O4 |
| 分子量 | 366.45 |
| 溶解度 | DMSO: 100 mg/mL (272.89 mM) |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is an intermediate of delta 9,11 steroids synthesis, for example, Vamorolone . The delta 9,11 steroids are modifications of glucocorticoids and has anti-inflammatory properties. The delta 9,11 steroids are agents for protection against cell damage (lipid peroxidation) and inhibition of neovascularization[1]. δ9,11 derivatives are designed and developed to stably incorporate into cell membranes and inhibit lipid peroxidation without glucocorticoid or mineralocorticoid activities, thus avoiding side effects associated with traditional corticosteroids[1].VBP15 acts as a lead compound due to potent NF-κB inhibition and GR translocation similar to prednisone and dexamethasone, lack of transactivation properties, and good bioavailability[1]. [1]. Erica K M Reeves, et al. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem |
m.cnreagent.com